Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2019

01-05-2019 | Review Article

Toll-like receptor 4 and breast cancer: an updated systematic review

Authors: Morteza Khademalhosseini, Mohammad Kazemi Arababadi

Published in: Breast Cancer | Issue 3/2019

Login to get access

Abstract

Toll-like receptors (TLRs) may play dual roles in human cancers. TLR4 is a key molecule which may participate in both friend and foe roles against breast cancer. This review article collected recent data regarding the mechanisms used by TLR4 in the eradication of breast cancer cells and induction of the tumor cells, and discussed the mechanisms involved in the various functions of TLR4. The literature searches revealed that TLR4 is a key molecule that participates in breast cancer cell eradication or induction of breast cancer development and also transformation of the normal cells. TLR4 eradicates breast cancer cells via recognition of their DAMPs and then induces immune responses. Over-expression of TLR4 and also alterations in its signaling, including association of some intrinsic pathways such as TGF-β signaling and TP53, are the crucial factors to alter TLR4 functions against breast cancer.
Literature
1.
Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59:651–72.CrossRefPubMed
2.
Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016;31:97–103.CrossRefPubMed
3.
Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem. 2007;100:1301–12.CrossRefPubMed
4.
Bagheri V, Askari A, Arababadi MK, Kennedy D. Can toll-like receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection? Hum Immunol. 2014;75:549–54.CrossRefPubMed
5.
Karimi-Googheri M, Arababadi MK. TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep. 2014;41:3279–86.CrossRefPubMed
6.
Imani Fooladi AA, Mousavi SF, Seghatoleslami S, Yazdani S, Nourani MR. Toll-like receptors: role of inflammation and commensal bacteria. Inflamm Allergy Drug Targets. 2011;10:198–207.CrossRefPubMed
7.
Sepehri Z, Kiani Z, Kohan F, Alavian SM, Ghavami S. Toll like receptor 4 and hepatocellular carcinoma; A systematic review. Life Sci. 2017;179:80–7.CrossRefPubMed
8.
Nguyen-Pham TN, Lim MS, Nguyen TA, Lee YK, Jin CJ, Lee HJ, et al. Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. Cell Mol Immunol. 2011;8:341–7.CrossRefPubMedPubMedCentral
9.
Hirayama T, Tamaki Y, Takakubo Y, Iwazaki K, Sasaki K, Ogino T, et al. Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. J Orthop Res. 2011;29:984–92.CrossRefPubMed
10.
Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009;104:210–8 (21p following 8).CrossRefPubMed
11.
12.
13.
Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640–3.CrossRefPubMed
14.
Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999;189:615–25.CrossRefPubMedPubMedCentral
15.
Zare-Bidaki M, Hakimi H, Abdollahi SH, Zainodini N, Kazemi Arababadi M, Kennedy D. TLR4 in Toxoplasmosis; friends or foe? Microb Pathog. 2014;69-70C:28–32.CrossRef
16.
Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell. 2006;125:943–55.CrossRefPubMed
17.
Cario E, Gerken G, Podolsky D. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359–74.CrossRefPubMed
18.
Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, et al. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J Exp Med. 2003;198:1043–55.CrossRefPubMedPubMedCentral
19.
Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–50.CrossRefPubMed
20.
Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol. 2010;87:989–99.CrossRefPubMed
21.
Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401.CrossRefPubMed
22.
Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389:847–60.CrossRefPubMed
23.
Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015;39:519–27.CrossRefPubMed
24.
Lee J, Choi J, Chung S, Park J, Kim JE, Sung H, et al. Genetic predisposition of polymorphisms in HMGB1-related genes to breast cancer prognosis in Korean women. J Breast Cancer. 2017;20:27–34.CrossRefPubMedPubMedCentral
25.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290–303.CrossRefPubMed
26.
Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7:1098–115.CrossRef
27.
Bhatt J, Desai A, Dave J, Juneja I, Meghani H, Shah M. Clinical study of CA breast & its surgical management. Int J Res Med. 2017;6:16–22.
28.
Park GS, Kim JH. Up-Regulates LPS. ICAM-1 expression in breast cancer cells by stimulating a MyD88-BLT2-ERK-linked cascade, which promotes adhesion to monocytes. Mol Cells. 2015;38:821–8.CrossRefPubMedPubMedCentral
29.
Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax(R), as a therapeutic strategy for metastatic breast cancer. J Transl Med. 2014;12:322.CrossRefPubMedPubMedCentral
30.
Ahmed A, Wang JH, Redmond HP. Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol. 2013;20(Suppl 3):389-96.
31.
Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology. 2012;1:271–8.CrossRefPubMedPubMedCentral
32.
Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026–30.CrossRefPubMed
33.
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.CrossRefPubMed
34.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.CrossRefPubMed
35.
Bergenfelz C, Medrek C, Ekstrom E, Jirstrom K, Janols H, Wullt M, et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol. 2012;188:5448–58.CrossRefPubMed
36.
Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17:1626–36.CrossRefPubMedPubMedCentral
37.
Lamrani M, Sassi N, Paul C, Yousfi N, Boucher JL, Gauthier N, et al. TLR4/IFNgamma pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models. Oncoimmunology. 2016;5:e1123369.CrossRefPubMed
38.
Zare-Bidaki M, Tsukiyama-Kohara K, Arababadi MK. Toll-like receptor 4 and hepatitis B infection: molecular mechanisms and pathogenesis. Viral Immunol. 2014;27:321–6.CrossRefPubMed
39.
Song Y, Shi Y, Ao LH, Harken AH, Meng XZ. TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta. World J Gastroenterol. 2003;9:1799–803.CrossRefPubMedPubMedCentral
40.
Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 2011;71:1989–98.CrossRefPubMed
41.
Chen Y, Wermeling F, Sundqvist J, Jonsson AB, Tryggvason K, Pikkarainen T, et al. A regulatory role for macrophage class A scavenger receptors in TLR4-mediated LPS responses. Eur J Immunol. 2010;40:1451–60.CrossRefPubMed
42.
Rittirsch D, Flierl MA, Day DE, Nadeau BA, Zetoune FS, Sarma JV, et al. Cross-talk between TLR4 and FcgammaReceptorIII (CD16) pathways. PLoS Pathog. 2009;5:e1000464.CrossRefPubMedPubMedCentral
43.
Volk-Draper LD, Hall KL, Wilber AC, Ran S. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4. PLoS One. 2017;12:e0179257.CrossRefPubMedPubMedCentral
44.
Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G. Significance of TLR4/MyD88 expression in breast cancer. Int J Clin Exp Pathol. 2015;8:7034–9.PubMedPubMedCentral
45.
Yang H, Wang B, Wang T, Xu L, He C, Wen H, et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One. 2014;9:e109980.CrossRefPubMedPubMedCentral
46.
Green TL, Santos MF, Ejaeidi AA, Craft BS, Lewis RE, Cruse JM. Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol. 2014;97:44–8.CrossRefPubMed
47.
Chalmers SA, Eidelman AS, Ewer JC, Ricca JM, Serrano A, Tucker KC, et al. A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol. 2013;282:136–45.CrossRefPubMedPubMedCentral
48.
Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S, et al. Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol. 2013;34:1053–9.CrossRefPubMed
49.
Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665.CrossRefPubMedPubMedCentral
50.
Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92.CrossRefPubMedPubMedCentral
51.
Ma FJ, Liu ZB, Hu X, Ling H, Li S, Wu J, et al. Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients. PLoS One. 2014;9:e111639.CrossRefPubMedPubMedCentral
52.
Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014;74:5421–34.CrossRefPubMedPubMedCentral
53.
54.
Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, et al. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 2015;17:130.CrossRefPubMedPubMedCentral
55.
Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy. Cancer Res. 2016;76:3122–6.CrossRefPubMed
56.
Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, et al. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 2017;9:357.
57.
Chang H, Wang Y, Yin X, Liu X, Xuan H. Ethanol extract of propolis and its constituent caffeic acid phenethyl ester inhibit breast cancer cells proliferation in inflammatory microenvironment by inhibiting TLR4 signal pathway and inducing apoptosis and autophagy. BMC Complement Altern Med. 2017;17:471.CrossRefPubMedPubMedCentral
58.
Edwardson DW, Boudreau J, Mapletoft J, Lanner C, Kovala AT, Parissenti AM. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. 2017;12:e0183662.CrossRefPubMedPubMedCentral
59.
Erez N, Glanz S, Raz Y, Avivi C, Barshack I. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013;437:397–402.CrossRefPubMed
60.
Wang M, Zhang J, Huang Y, Ji S, Shao G, Feng S, et al. Cancer-associated fibroblasts autophagy enhances progression of triple-negative breast cancer cells. Med Sci Monit. 2017;23:3904–12.CrossRefPubMedPubMedCentral
61.
Zhao XL, Lin Y, Jiang J, Tang Z, Yang S, Lu L, et al. High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells. J Pathol. 2017;243:376–89.CrossRefPubMed
62.
Han L, Liu B, Jiang L, Liu J, Han S. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha. Tumour Biol. 2016;37:13205–14.CrossRefPubMed
63.
Xu M, Wang HF, Zhang YY, Zhuang HW. Protection of rats spinal cord ischemia-reperfusion injury by inhibition of MiR-497 on inflammation and apoptosis: possible role in pediatrics. Biomed Pharmacother. 2016;81:337–44.CrossRefPubMed
64.
Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, et al. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer. 2012;131:E884-96.CrossRefPubMed
65.
Tosun S, Fried S, Niggemann B, Zanker KS, Dittmar T. Hybrid cells derived from human breast cancer cells and human breast epithelial cells exhibit differential TLR4 and TLR9 signaling. Int J Mol Sci. 2016;17:726.CrossRefPubMedCentral
66.
Fried S, Tosun S, Troost G, Keil S, Zaenker KS, Dittmar T. Lipopolysaccharide (LPS) promotes apoptosis in human breast epithelial × breast cancer hybrids, but not in parental cells. PLoS One. 2016;11:e0148438.CrossRefPubMedPubMedCentral
67.
68.
Lv W, Chen N, Lin Y, Ma H, Ruan Y, Li Z, et al. Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis. Cancer Lett. 2016;375:245–55.CrossRefPubMed
69.
Bergenfelz C, Gaber A, Allaoui R, Mehmeti M, Jirstrom K, Leanderson T, et al. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. Br J Cancer. 2015;113:1234–43.CrossRefPubMedPubMedCentral
70.
Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008;8:243–52.CrossRefPubMed
71.
Xu F, Wang F, Yang T, Sheng Y, Zhong T, Chen Y. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int. 2014;14:142.PubMedPubMedCentral
72.
Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res. 2013;19:6074–83.CrossRefPubMedPubMedCentral
73.
Zhou YH, Liao SJ, Li D, Luo J, Wei JJ, Yan B, et al. TLR4 ligand/H(2)O(2) enhances TGF-beta1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways. PLoS One. 2013;8:e65906.CrossRefPubMedPubMedCentral
74.
Li J, Yin J, Shen W, Gao R, Liu Y, Chen Y, et al. TLR4 promotes breast cancer metastasis via Akt/GSK3beta/beta-catenin pathway upon LPS stimulation. Anat Rec (Hoboken). 2017;300:1219–29.CrossRef
75.
Egunsola AT, Zawislak CL, Akuffo AA, Chalmers SA, Ewer JC, Vail CM, et al. Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol. 2012;272:220–9.CrossRefPubMed
76.
Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, et al. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes alphavbeta3-mediated adhesion and invasive migration. Breast Cancer Res Treat. 2012;133:853–63.CrossRefPubMed
77.
Petricevic B, Vrbanec D, Jakic-Razumovic J, Brcic I, Rabic D, Badovinac T, et al. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol. 2012;29:486–94.CrossRefPubMed
78.
Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci USA. 2015;112:E3216-25.CrossRefPubMed
79.
Oliveira TF, Maues T, Ramundo MS, Figueiredo AMS, de Mello MFV, El-Jaick KB, et al. TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas. J Vet Diagn Invest. 2017;29:865–8.CrossRefPubMed
80.
Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012;131:1169–78.CrossRefPubMed
81.
Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res. 2004;10:6208–14.CrossRefPubMed
82.
Slattery ML, Lundgreen A, Torres-Mejia G, Wolff RK, Hines L, Baumgartner K, et al. Diet and lifestyle factors modify immune/inflammation response genes to alter breast cancer risk and prognosis: the Breast Cancer Health Disparities Study. Mutat Res. 2014;770:19–28.CrossRefPubMedPubMedCentral
83.
Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 polymorphisms with risk of cancer: a meta-analysis. PLoS One. 2013;8:e82858.CrossRefPubMedPubMedCentral
84.
Yang CX, Li CY, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens. 2013;81:221–6.CrossRefPubMed
85.
Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21:534–8.CrossRefPubMed
86.
Semlali A, Jalouli M, Parine NR, Al Amri A, Arafah M, Al Naeem A, et al. Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. Onco Targets Ther. 2017;10:1207–16.CrossRefPubMedPubMedCentral
Metadata
Title
Toll-like receptor 4 and breast cancer: an updated systematic review
Authors
Morteza Khademalhosseini
Mohammad Kazemi Arababadi
Publication date
01-05-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-00935-2

Other articles of this Issue 3/2019

Breast Cancer 3/2019 Go to the issue

Original Article

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients

Original Article

Identification of genes associated with survival of breast cancer patients

Original Article

Physical activity and physiotherapy: perception of women breast cancer survivors

Original Article

Can quantitative evaluation of mammographic breast density, “volumetric measurement”, predict the masking risk with dense breast tissue? Investigation by comparison with subjective visual estimation by Japanese radiologists

Original Article

Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity

Original Article

Clinicopathological features of breast cancer in Japanese female patients with Lynch syndrome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits